Novel 99mTc labeled σ receptor ligand as a potential tumor imaging agent

A novel ^99mTc labeled complex, [N-[2-((2-oxo-2-(4-(3-phenylpropyl)piperazin-1-yl)ethyl) (2-mercaptoethyl)amino)acetyl]-2-aminoethanethiolato]Technetium(V) oxide (PPPE-MAMA’-^99mTcO) ([ ^99m Tc]-2) has been designed and prepared based on the integrated approach. The corresponding rhenium complex (PPPE-MAMA’-ReO)(Re-2) has been prepared and characterized. In vitro competition binding assays show moderate affinity of Re-2 towards σ₁ and σ₂ receptors with K _i values of 8.67 ± 0.07 and 5.71 ± 1.88 μmol, respectively. Planar images obtained at 0.5 h, 4 h, 20 h after i.v. injection indicate the accumulation of [ ^99m Tc]-2 in MCF-7 human breast tumor bearing mice at 20 h. Furthermore, the accumulation of [ ^99m Tc]-2 has been inhibited at 20 h after co-injection of [ ^99m Tc]-2 plus haloperidol (1 mg/kg). Biodistribution studies of [ ^99m Tc]-2 display an in vivo tumor uptake of 0.14% ± 0.01% ID/g at 24 h post i.v. injection with a tumor/muscle ratio of 6.02 ± 0.87. The above results suggest that [ ^99m Tc]-2, derived from a previously published lead compound, retains certain tumor uptake and affinity for σ receptors. [ ^99m Tc]-2 may be used as a basis for further structural modifications to develop tumor imaging agents with high affinity for σ receptors.     

The influence of stereoisomerism on the biological behavior of 99mTc labeled penicillamine

The aim of this study is to investigate stereoisomeric behavior of penicillamine and the effect of temperature on labeling. In addition, it was explored how stereoisomerism affected biological behavior of them. In the present work, D- and L-enantiomers of penicillamine(D-PA, L-PA) were labeled with ^99mTc using SnCl₂ as reducing agent and their radiopharmaceutical potentials were investigated. Quality control procedures were carried out using thin layer radiochromatography (TLRC), electrophoresis and high performance liquid radiochromatography (HPLRC). HPRLC chromatograms showed two peaks for ^99mTc-D-PA, while a single peak was observed for ^99mTc-L-PA at room temperature. However, the single peak was observed at 90 °C for both isomers. Labeling yields of each isomer were found to be over 98%. Biological activity of these complexes was determined on male Albino Wistar rats by biodistribution studies. While the biodistribution result of ^99mTc-D-PA showed high uptake in the liver, maximum uptake of ^99mTc-L-PA was observed in the kidneys. Both two complexes were cleared rapidly from the blood, mainly by the renal system. Since the activity concentration of ^99mTc-D-PA at the 30th minute in the kidneys and the liver reached a maximum value and at the 120th minute, it was removed by renal and hepatobiliary excretion. As a result, it can be concluded that stereoisomerism affect not only the chemical behavior, but also differs their biological behavior of these compounds.     

Tc标记的叶酸肿瘤显像剂

叶酸受体在许多源于上皮组织的恶性肿瘤中高度表达,是目前肿瘤放射性显像研究的一个新的靶点。由于叶酸对于叶酸受体具有很高的亲和性,作为重要的特异性靶向介导分子,^99mTc标记叶酸肿瘤显像剂已成为当前放射性药物的研究热点之一。本文对不同类型的^99mTc标记的叶酸类放射性肿瘤显像剂的研究进展、应用情况和存在的问题进行了评述,探讨了^99mTc标记叶酸显像剂的一般设计方法,并对其未来发展方向进行了展望。     

Radiosynthesis and in vitro evaluation of 99mTc(CO)3-labeled folic acid derivative

The over-expression of folate receptors in variety of neoplastic tissues makes radiolabeled folate conjugates potential agents for imaging and therapy of such cancers. With the aim of preparing an imaging agent for targeting folate receptors, folic acid has been conjugated with homocysteine for complexation with [^99mTc(CO)₃(H₂O)₃]⁺ core. The radiolabeled complex of the homocysteine-folate could be obtained in >95% radiochemical yield as observed by HPLC. Stability of complex in saline was studied and challenge studies with histidine and cysteine revealed kinetic stability of the complex. Lipophilicity of the radiolabeled complex (log P) was found to be 0.45. In vitro uptake of ^99mTc(CO)₃-labeled folic acid derivative was studied in KB cells and inhibition studies were carried out using ³H-folic acid and cold homocysteine–folate conjugate. The in vitro studies indicated loss of binding affinity of the derivative towards folate receptors.     

Synthesis of a bis-(N-butyl-dithiocarbamato)-nitrido 99mTc complex: A potential new brain imaging agent

The bis(N-butyl dithiocarbamato) nitrido ^99mTc complex [^99mTcN(BDTC)₂] (BDTC: N-butyl dithiocarbamato) has been synthesized through a ligand-exchange reaction. The two-step procedure consisted of an initial reaction of ^99mTcO₄ ⁻ with succinic dihydrazide (SDH) in the presence of stannous chloride as reducing agent and propylenediamine tetraacetic acid (PDTA) as complexing agent, and subsequent addition of sodium salt of N-butyl dithiocarbamate. The radiochemical purity of the complex was over 90%, as measured by thin layer chromatography. No decomposition of the complex at room temperature was observed over a period of 6 hours. Its partition coefficient indicated that it was a lipophilic complex. The electrophoresis results showed the complex was neutral. Biodistribution in mice showed that the complex accumulated in the brain with high uptake. The brain/blood ratio was 1.58, 1.67 and 1.20 at 5, 30 and 60-minute post-injection, respectively, suggesting this compound would be a potential cerebral imaging agent.     

Evaluation of highly loaded low specific activity 99Mo on alumina column as 99mTc generator

Adsorption behavior of molybdate on acidic alumina was studied at boiling water bath temperature (~100 °C). Various parameters affecting the adsorption of molybdenum, such as pH, amount of molybdenum, incubation period, etc., were determined. A ^99mTc generator was prepared by adsorbing low specific activity ⁹⁹Mo (150 mg) on 1 g alumina. Elutions were carried out with saline. Performance of the generator such as ⁹⁹Mo breakthrough, aluminum contents, pH, elution profile, radiochemical purity, and labeling efficiency of kits were checked.     

99mTc-AMD3100: A novel potential receptor-targeting radiopharmaceutical for tumor imaging

<正>The chemokine CXCR4 receptor is over-expressed in a wide variety of tumors.In this study,AMD3100,which was a prototype non-peptide antagonist of CXCR4 receptor,was labeled with ~(99m)Tc.~(99m)Tc-AMD3100 was verified by thin layer radio chromatography(TLRC).The tumor-localizing properties of ~(99m)Tc-AMD3100 were evaluated and proved in mice bearing Hep-G2 tumor xenograft.~(99m)Tc-AMD3100 was a promising,novel receptor-specific radiopharmaceutical with potential application in the imaging of human tumors.     

Zur Abtrennung des medizinisch wichtigen 99mTc von bestrahltem Molybd?n

Ohne Zusammenfassung     

Evaluation of a new radiolabeled bombesin derivative with 99mTc as potential targeted tumor imaging agent

Gastrin-releasing peptide (GRP) receptors are over-expressed in various human tumor including breast and prostate which can be targeted with bombesin for diagnosis and targeted therapy. High abdominal accumulation and the poor in vivo stability of radiolabeled bombesin analogues may represent a limitation for diagnostic imaging and targeted therapy. In this study a new bombesin derivative was labeled with ^99mTc via HYNIC and tricine as a coligand and investigated further. The peptide HYNIC conjugate was synthesized on a solid phase using Fmoc strategy. Labeling with ^99mTc was performed at 100 °C for 10 min and radiochemical analysis involved ITLC and HPLC methods. The stability of radiopeptide was checked in the presence of human serum at 37 °C up to 24 h. Internalization was studied with the human GRP receptor cell line PC-3. The Biodistribution was studied in mice. Labeling yield of >98 % was obtained to correspond a specific activity of ~80.9 GBq/μmol. Radioconjugate internalization into PC-3 cells was high and specific (15.6 ± 1.9 % at 4 h). A high and specific uptake in GRP-receptor-positive organs such as mouse tumor and pancreas (2.11 ± 0.18 and 1.78 ± 0.09 % ID/g after 1 h respectively) was also determined.     

Synthesis, biodistribution and evaluation of 99mTc-sitafloxacin kit: a novel infection imaging agent

Radiosynthesis of ^99mTc-sitafloxacin (^99mTc-STF) complex and its efficacy as a potential infection imaging agent was evaluated. Effect of sitafloxacin (STF) concentration, sodium pertechnetate (Na^99mTcO₄), stannous chloride dihydrate (SnCl₂·2H₂O), and pH on the % radiochemical purity yield (RCP) of ^99mTc-STF complex was studied. A stable ^99mTc-STF complex up to 120 min with maximum %RCP yield was observed by mixing 2 mg of STF with 3 mCi of Na^99mTcO₄ and 150 μL of SnCl₂·2H₂O (1 μg/μL in 0.01 N HCl) at a pH 5.5. Artificially infected rats with Staphylococcus aureus were used for studying the biodistribution behavior of the ^99mTc-STF complex. After 30 min of the intravenous (I.V.) administration of the ^99mTc-STF complex, 7.50 ± 0.10% was absorbed in the infected thigh of the rats and the uptake gradually increased to 18.50 ± 0.20% within 90 min. Rabbits with artificially induced infection were used for evaluating the scintigraphic accuracy. Higher uptake in the infected thigh was observed after 2 h of I.V. administration of the ^99mTc-STF complex. Target to non-target organ ratio of the % absorbed dose incase of infected/normal muscle was 6.82 ± 0.40, 17.11 ± 0.60, and 23.13 ± 1.00% at 30, 60 and 90 min of administration. Stable and higher %RCP, higher uptake in the infected thigh, and spectral studies, recommend the ^99mTc-STF for routine infection imaging.     

Synthesis and biodistribution of 99mTc(CO)3-DMSA-MIBI in mice

Mixed ligand fac-tricarbonyl complex of [^99mTc(CO)₃-DMSA-MIBI] has been prepared starting from the precursor [^99mTc(OH₂)₃(CO)₃]⁺. The complex can be obtained in good yield and purity in a two-step procedure by first attaching meso-2,3-dimercaptosuccinic acid (DMSA, HOOCCH(SH)CH(SH)COOH) with [^99mTc(OH₂)₃(CO)₃]⁺, followed by addition of MIBI [tetrakis-2-methoxyisobutylisonitrile (CH₃OC(CH₃)₂CH₂-N≡C) copper(I) tetrafluoroborate] solution. The complex was characterized by TLC and HPLC and was studied by means of octanol-water partition coefficient, electrophoresis, stability in vitro, and normal mice experiment. Biodistribution in mice demonstrated that the complex showed higher myocardial uptake after 0.5-hour p.i. The ratios of heart/liver (%ID/g) in the case of ^99mTc(CO)₃-DMSA-MIBI was higher (1.88) than that observed in case of ^99mTc-MIBI¹ (0.93) after 0.5-hour p.i. (P<0.05). Results showed that the complex may be developed to a novel myocardial perfusion-imaging agent.     

Synthesis and biodistribution of two novel 99mTc nitrido dithiocarbamate complexes containing heterocyclic linkage as potential brain perfusion imaging agents

Various plutonium compounds are handled in nuclear facilities of BARC. Hence, there is a possibility of occupational workers getting exposed to Pu. In vitro bioassay monitoring in which Pu is separated by chemical procedures from excreta samples and estimated by alpha-spectrometry, is the method of choice for the evaluation of internal dose to the occupational workers handling Pu. However, this method requires a suitable Pu tracer for reducing the uncertainties due to chemical yield in the separation, electro-deposition and counting efficiency. ²⁴²Pu is commonly used as a tracer but due to its non-availability, efforts were made earlier to indigenously synthesis ²³⁶Pu by proton irradiation of ²³⁷Np in BARC-TIFR pelletron facility. The present study, reports the feasibility of using ²³⁶Pu as a radiochemical yield monitor (tracer) in bioassay samples.     

Die Bestimmung von 235U durch Neutronenaktivierung und Abtrennung von 99Mo99mTc mit Hilfe des Ringofens.

Ohne Zusammenfassung     

Preparation and evaluation of a new neurotensin analog labeled with 99mTc for targeted imaging of neurotensin receptor positive tumors

Neurotensin receptors are overexpressed in several human tumors and can be targets for tumors diagnosis and therapy. In this study, a new neurotensin analogue was labeled with ^99mTc via HYNIC and tricine/EDDA as coligands and investigated further. [HYNIC⁰, Gly⁷, Lys⁹, d-Tyr¹¹]-Neurotensin (7–13) was synthesized using a standard Fmoc strategy. Labeling with ^99mTc was performed at 100 °C for 10 min and radiochemical analysis involved ITLC and HPLC methods. The stability of radiopeptide was checked in the presence of humane serum at 37 °C up to 24 h. The receptor bound internalization and externalization rates were studied in neurotensin receptor expressing HT-29 cells. Biodistribution of radiopeptide was studied in nude mice bearing HT-29 tumor. Labeling yield of 98.6 ± 0.54 % (n = 3) was obtained corresponding to a specific activity of 81 MBq/nmol. Peptide conjugate showed good stability in the presence of human serum. The radioligand showed specific internalization into HT-29 cells (12.43 ± 0.52 % at 4 h). In biodistribution studies, a receptor-specific uptake was observed in neurotensin receptor positive organs so that after 1 h the uptakes in mouse intestine and tumor were 0.87 ± 0.16 and 0.63 ± 0.12 % ID/g respectively.     

Optimization of the reaction conditions for the preparation of 99mTc-celecoxib and its biological evaluation

Celecoxib was labelled effectively with ^99mTc. The labeling yield was found to be influenced by the amount of celecoxib, the amount of stannous chloride dihydrate, the reaction time, the temperature and the pH of the reaction mixture. The importance of stannous chloride dihydrate arises from its function as a reducing agent for pertechnetate to form complex celecoxib. The suitable amount required to produce high labeling yield of ^99mTc-celecoxib was 500 μg SnCl₂·2H₂O. The pH of the reaction medium was found to play a significant role in this labeling process. The labeling reaction was performed at a neutral medium (pH 7). The labeling reaction proceeds well at room temperature (25 ± 1 °C) and the complex decomposes by heat. The labeled celecoxib (^99mTc-celecoxib) showed a good localization in inflamed foci and a good imaging must be taken 4 h post injection.     

Synthesis and evaluation of a new bombesin analog labeled with <Superscript>99m</Superscript>Tc as a GRP receptor imaging agent

Tumors such as prostate, small cell lung cancer, breast, gastric and colon cancer are known to overexpress receptors to bombesin (BBN). In this study, a new bombesin analogue was labeled with ^99mTc via HYNIC and tricine/EDDA as coligands and investigated further. HYNIC-GABA-Bombesin (7–14) NH₂ was synthesized using a standard Fmoc strategy. Labeling with ^99mTc was performed at 100 °C for 10 min and radiochemical analysis involved ITLC and HPLC methods. The stability of radiopeptide was checked in the presence of humane serum at 37 °C up to 24 h. The receptor bound internalization and externalization rates were studied in GRP receptor expressing PC-3 cells. Biodistribution of radiopeptide was studied in nude mice bearing PC-3 tumor. Labeling yield of >98% was obtained corresponding to a specific activity of ~2.6 MBq/nmol. Peptide conjugate showed good stability in the presence of human serum. The radioligand showed high and specific internalization into PC-3 cells (14.63 ± 0.41% at 4 h). In biodistribution studies, a receptor-specific uptake was observed in GRP-receptor-positive organs so that after 4 h the uptakes in mouse tumor and pancreas were 1.31 ± 0.18 and 1.2 ± 0.13% ID/g, respectively.     

Determination of 99Tc in evaporator concentrates using solid phase extraction techniques

This paper describes a simple and rapid method of ⁹⁹Tc pre-concentration, separation and purification by using AnaLig^? Tc02 gel in two stages or AnaLig^? Tc02 gel in a first stage and TEVA^? resin in a second stage, which are commercially available from IBC advanced technologies, Inc. and Eichrom technologies, Inc., respectively. The method is suitable for analyzing large volume concentrate samples in a relatively short time. The use and effectiveness of AnaLig^? Tc02 and Eichrom’s TEVA^? resin were successfully tested by analysis of evaporator concentrate samples which belong to the class of most difficult matrices to analyze.     

Preparation and biological evaluation of radiogallium labeled glucagon for SPECT imaging

In this work, recently prepared ⁶⁷Ga-labeled glucagon (⁶⁷Ga-DTPA-GCG) for imaging studies (radiochemical purity >94%; HPLC, S.A. 296–370 GBq/mM) was used in biological studies. The wild-type rat biodistribution results, 2 h post injection, demonstrated high tissue:muscle ratios for target tissues (liver, kidney, heart, spleen, fat intestine stomach and pancreas), 234, 18.45, 7.12, 1.75, 128.7, 4.9, 6.3 and 1.11, respectively. The tracer binding capacity using freshly prepared rat brain homogenate demonstrated significant specific binding of the tracer to neuronal GCG receptors (⁶⁷Ga-DTPA-GCG/⁶⁷Ga:3 and ⁶⁷Ga-DTPA-GCG/⁶⁷GaDTPA:2.2 at 90 min). SPECT images also demonstrated target specific binding of the tracer at 4 h. The data suggests the tracer is accumulated in GCGR rich tissues 2–4 h post injection, suggesting potentials of the tracer for future imaging studies in glocagonoma models.     

Novel 99mTc labeled σ receptor ligand as a potential tumor imaging agent

A novel 99mTc labeled complex, [N-[2-((2-oxo-2-(4-(3-phenylpropyl)piperazin-1-yl)ethyl) (2-mercaptoethyl)amino)acetyl]-2-aminoethanethiolato]Technetium(V) oxide (PPPE-MAMA′-99mTcO) ([99mTc]-2) has been designed and prepared based on the integrated approach. The corresponding rhenium complex (PPPE-MAMA′-ReO)(Re-2) has been prepared and characterized. In vitro competition binding assays show moderate affinity of Re-2 towards σ1 and σ2 receptors with Ki values of 8.67 ± 0.07 and 5.71 ± 1.88 μmol, respectively. Planar images obtained at 0.5 h, 4 h, 20 h after I.v. Injection indicate the accumulation of [99mTc]-2 in MCF-7 human breast tumor bearing mice at 20 h. Furthermore, the accumulation of [99mTc]-2 has been inhibited at 20 h after co-injection of [99mTc]-2 plus haloperidol (1 mg/kg). Biodistribution studies of [99mTc]-2 display an in vivo tumor uptake of 0.14% ± 0.01% ID/g at 24 h post I.v. Injection with a tumor/muscle ratio of 6.02 ± 0.87. The above results suggest that [99mTc]-2, derived from a previously published lead compound, retains certain tumor uptake and affinity for σ receptors. [99mTc]-2 may be used as a basis for further structural modifications to develop tumor imaging agents with high affinity for σ receptors.